Cite
Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent lymphomas: Nine-year updated results from the StiL NHL1 study
MLA
Heinz Dürk, et al. “Bendamustine plus Rituximab (B-R) versus CHOP plus Rituximab (CHOP-R) as First-Line Treatment in Patients with Indolent Lymphomas: Nine-Year Updated Results from the StiL NHL1 Study.” Journal of Clinical Oncology, vol. 35, May 2017, p. 7501. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........e9bc7c478904cee9c3e2184351e950fa&authtype=sso&custid=ns315887.
APA
Heinz Dürk, Georg Maschmeyer, Harald Ballo, Manfred Welslau, Eckhart Weidmann, Christina Balser, Ulrich Kaiser, Christoph Losem, Alexander Burchardt, Wolfram Brugger, Gerhard Heil, Frank Kauff, Ulrich von Gruenhagen, Wolfgang Blau, Martina Stauch, Andrea Heider, Mathias J. Rummel, Arnold Ganser, & Juergen Barth. (2017). Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent lymphomas: Nine-year updated results from the StiL NHL1 study. Journal of Clinical Oncology, 35, 7501.
Chicago
Heinz Dürk, Georg Maschmeyer, Harald Ballo, Manfred Welslau, Eckhart Weidmann, Christina Balser, Ulrich Kaiser, et al. 2017. “Bendamustine plus Rituximab (B-R) versus CHOP plus Rituximab (CHOP-R) as First-Line Treatment in Patients with Indolent Lymphomas: Nine-Year Updated Results from the StiL NHL1 Study.” Journal of Clinical Oncology 35 (May): 7501. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........e9bc7c478904cee9c3e2184351e950fa&authtype=sso&custid=ns315887.